Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1.

McCaw TR, Li M, Starenki D, Liu M, Cooper SJ, Arend RC, Forero A, Buchsbaum DJ, Randall TD.

Cancer Immunol Immunother. 2019 Dec;68(12):2081-2094. doi: 10.1007/s00262-019-02430-9. Epub 2019 Nov 12.

PMID:
31720815
2.

Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.

Dockery LE, Rubenstein AR, Ding K, Mashburn SG, Burkett WC, Davis AM, Doo DW, Arend RC, Moore KN, Gunderson CC.

Gynecol Oncol. 2019 Nov;155(2):201-206. doi: 10.1016/j.ygyno.2019.07.008. Epub 2019 Sep 12.

PMID:
31522837
3.

Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.

Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA.

Future Oncol. 2019 Oct;15(28):3267-3281. doi: 10.2217/fon-2019-0368. Epub 2019 Aug 9.

4.

A Ketogenic Diet Is Acceptable in Women with Ovarian and Endometrial Cancer and Has No Adverse Effects on Blood Lipids: a Randomized, Controlled Trial.

Cohen CW, Fontaine KR, Arend RC, Gower BA.

Nutr Cancer. 2019 Jul 27:1-11. doi: 10.1080/01635581.2019.1645864. [Epub ahead of print]

PMID:
31352797
5.

Checkpoint inhibitors in ovarian cancer: A review of preclinical data.

Doo DW, Norian LA, Arend RC.

Gynecol Oncol Rep. 2019 Jun 18;29:48-54. doi: 10.1016/j.gore.2019.06.003. eCollection 2019 Aug. Review.

6.

A Review of the Role of Wnt in Cancer Immunomodulation.

Goldsberry WN, Londoño A, Randall TD, Norian LA, Arend RC.

Cancers (Basel). 2019 Jun 4;11(6). pii: E771. doi: 10.3390/cancers11060771. Review.

7.

Advancing Drug Development in Gynecologic Malignancies.

Beaver JA, Coleman RL, Arend RC, Armstrong DK, Bala S, Mills GB, Sood AK, Herzog TJ.

Clin Cancer Res. 2019 Aug 15;25(16):4874-4880. doi: 10.1158/1078-0432.CCR-19-0619. Epub 2019 May 24.

PMID:
31126961
8.

Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer.

Roane BM, Arend RC, Birrer MJ.

Cancers (Basel). 2019 May 14;11(5). pii: E668. doi: 10.3390/cancers11050668. Review.

9.

Revisiting entinostat as an immune-potentiating adjuvant.

McCaw TR, Randall TD, Arend RC.

Oncotarget. 2018 Dec 18;9(99):37278-37279. doi: 10.18632/oncotarget.26453. eCollection 2018 Dec 18. No abstract available.

10.

The antitumor effects of entinostat in ovarian cancer require adaptive immunity.

Smith HJ, McCaw TR, Londono AI, Katre AA, Meza-Perez S, Yang ES, Forero A, Buchsbaum DJ, Randall TD, Straughn JM Jr, Norian LA, Arend RC.

Cancer. 2018 Dec 15;124(24):4657-4666. doi: 10.1002/cncr.31761. Epub 2018 Nov 13.

PMID:
30423192
11.

The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.

McCaw TR, Li M, Starenki D, Cooper SJ, Liu M, Meza-Perez S, Arend RC, Buchsbaum DJ, Forero A, Randall TD.

Cancer Immunol Immunother. 2019 Feb;68(2):175-188. doi: 10.1007/s00262-018-2262-5. Epub 2018 Oct 17.

PMID:
30334128
12.

Favorable Effects of a Ketogenic Diet on Physical Function, Perceived Energy, and Food Cravings in Women with Ovarian or Endometrial Cancer: A Randomized, Controlled Trial.

Cohen CW, Fontaine KR, Arend RC, Soleymani T, Gower BA.

Nutrients. 2018 Aug 30;10(9). pii: E1187. doi: 10.3390/nu10091187.

13.

Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.

Arend RC, Toboni MD, Montgomery AM, Burger RA, Olawaiye AB, Monk BJ, Herzog TJ.

Oncologist. 2018 Dec;23(12):1533-1545. doi: 10.1634/theoncologist.2018-0095. Epub 2018 Aug 23.

14.

A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer.

Cohen CW, Fontaine KR, Arend RC, Alvarez RD, Leath CA III, Huh WK, Bevis KS, Kim KH, Straughn JM Jr, Gower BA.

J Nutr. 2018 Aug 1;148(8):1253-1260. doi: 10.1093/jn/nxy119.

PMID:
30137481
15.

FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.

Kreitzburg KM, Fehling SC, Landen CN, Gamblin TL, Vance RB, Arend RC, Katre AA, Oliver PG, van Waardenburg RCAM, Alvarez RD, Yoon KJ.

Cancer Lett. 2018 Nov 1;436:75-86. doi: 10.1016/j.canlet.2018.08.015. Epub 2018 Aug 16.

16.

Overcoming immune suppression with epigenetic modification in ovarian cancer.

McCaw TR, Randall TD, Arend RC.

Transl Res. 2019 Feb;204:31-38. doi: 10.1016/j.trsl.2018.06.003. Epub 2018 Jun 23. Review.

PMID:
30048638
17.

Disparities in receipt of follow-up care instructions among female adult cancer survivors: Results from a national survey.

Wu J, Blair J, Izevbigie OC, Wright NC, Arend RC.

Gynecol Oncol. 2018 Sep;150(3):494-500. doi: 10.1016/j.ygyno.2018.06.024. Epub 2018 Jun 30.

PMID:
29970241
18.

Endometrial cancer: Molecular markers and management of advanced stage disease.

Arend RC, Jones BA, Martinez A, Goodfellow P.

Gynecol Oncol. 2018 Sep;150(3):569-580. doi: 10.1016/j.ygyno.2018.05.015. Epub 2018 May 27. Review.

PMID:
29843906
19.

Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Jones BA, Varambally S, Arend RC.

Mol Cancer Ther. 2018 Mar;17(3):591-602. doi: 10.1158/1535-7163.MCT-17-0437. Review.

20.

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.

Arend RC, Londoño-Joshi AI, Gangrade A, Katre AA, Kurpad C, Li Y, Samant RS, Li PK, Landen CN, Yang ES, Hidalgo B, Alvarez RD, Straughn JM, Forero A, Buchsbaum DJ.

Oncotarget. 2018 Apr 10;9(27):19459. doi: 10.18632/oncotarget.25151. eCollection 2018 Apr 10.

Supplemental Content

Loading ...
Support Center